Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models. - Wikidata - wikimedia - TriplyDB

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

http://www.wikidata.org/entity/Q34150018

about

The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy HDAC inhibitors and immunotherapy; a double edged sword?IL-17+Foxp3+ T cells: an intermediate differentiation stage between Th17 cells and regulatory T cells Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma Epigenetics in Cancer: A Hematological Perspective ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.The narrow-spectrum HDAC inhibitor entinostat enhances NKG2D expression without NK cell toxicity, leading to enhanced recognition of cancer cells Entinostat is a histone deacetylase inhibitor selective for class 1 histone deacetylases and activates HIV production from latently infected primary T cells.Epigenetic enzymes are the therapeutic targets for CD4(+)CD25(+/high)Foxp3(+) regulatory T cells Ginsenoside Rg3 inhibits melanoma cell proliferation through down-regulation of histone deacetylase 3 (HDAC3) and increase of p53 acetylation.Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine.Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.γδ T cells and epigenetic drugs: A useful merger in cancer immunotherapy?Targeting Histone Deacetylases in Diseases: Where Are We?ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer.Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.HDAC 1 and 6 modulate cell invasion and migration in clear cell renal cell carcinoma.HDAC inhibition suppresses primary immune responses, enhances secondary immune responses, and abrogates autoimmunity during tumor immunotherapy.Entinostat up-regulates the CAMP gene encoding LL-37 via activation of STAT3 and HIF-1α transcription factors.The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinosta Potential biofluid markers and treatment targets for renal cell carcinoma.The emerging role of histone deacetylase (HDAC) inhibitors in urological cancers.The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.Entinostat: a promising treatment option for patients with advanced breast cancer.Marked for death: targeting epigenetic changes in cancer.Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy Histone deacetylase inhibitors as immunomodulators in cancer therapeutics.Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.Epigenetic approach for angiostatic therapy: promising combinations for cancer treatment.Cdk5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex.Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy.Prognostic and biological significance of survivin expression in patients with diffuse large B-cell lymphoma treated with rituximab-CHOP therapy.Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.HDAC inhibitors and their potential applications to glioblastoma therapy.

P2860

Q26745842-1CFA040F-F5B6-418F-BC87-4732825B7FE4 Q26825053-921D36C8-9691-48C0-B398-569485634155 Q26853102-360C8E11-4986-4845-828D-D58206811776 Q26996213-09E34590-7C30-4C52-8A1F-A961A26056E9 Q27025984-5DAE1637-3B1F-4D7C-8215-975757C17610 Q28077082-36B2DB7A-370F-4A40-B4CB-192CDB221546 Q33432027-7101C42D-2B96-4667-8F45-BF9AB93B5C09 Q33435113-2B45C98D-59FC-4C30-8C79-D2891E48683B Q33584049-C8555C16-A317-47E8-9981-2360A56C01B1 Q33838633-1348CB27-A0FB-4274-9814-CD2F268E2810 Q34656908-09709515-72FB-468F-9CBE-6CCD09A6A264 Q34734168-8713EE49-A99D-4458-A9E9-867BE853FCB8 Q34935239-5380AB6B-F223-408B-BAFE-90AEBE045789 Q35071167-C7279EE1-4FCD-430C-90AC-B27B3D885F18 Q35103991-36E39016-96A5-49EA-9734-71D31846AA14 Q35799192-6D67B70E-CC57-4B5C-8C32-03AD73AE9E06 Q35821728-3F5B326A-AFFC-4F46-A982-D311D0AEE1DB Q36051831-E2243C51-18C4-487B-97B4-4112ADFD6C14 Q36086345-8BD8AB53-35C4-44E3-BB57-DDCF6EEF3450 Q36099567-44561AF8-C365-4661-AC02-CE3EA7DE2A66 Q36740297-6B2A5D54-694C-4A68-8379-AA60B2C3A447 Q37260765-E911536A-56CF-4924-AE2E-2F1EDD6315D0 Q37477372-5F668935-1B32-4625-B6CD-E8FE884E45CF Q38094918-0011141E-403A-4650-A0A7-A7D48AA11B1A Q38095611-A420D363-7229-4329-B3B1-231583D40124 Q38203779-C5D0D57B-5498-4475-BCDC-F61E3D932BEA Q38240733-EA32B0C4-B6CB-4679-9BFE-8EB7C1DAD7A3 Q38537768-1CC4CF84-195F-4722-A795-75E847E90F70 Q38683494-470893B1-F128-4F75-BE3A-222613B53272 Q38741783-531AA68D-93BA-4E3A-AEC9-57D0E2422B4E Q38747872-B6D30682-C702-4A8B-A860-F44C6B8FF278 Q38749824-14F33FEE-41B6-4865-9745-564867BE131B Q38763747-CF3F7E4F-C339-437F-8871-BFC586D9874A Q38838643-FCA08E43-7912-4707-AF11-067B69B8CE6A Q39220891-929EC23E-9524-4BBE-AFB2-CB1C5F1AF8CF Q41198721-8CDF2108-F8C4-478A-B116-9D922959E07B Q41474934-33AE7E64-B32E-4EAD-9A1D-D8556FCF5466 Q41507351-446C523D-0373-494E-960C-D4F5A834585C Q41633683-727C6D9A-459D-486E-934F-F52DB04C4CBA Q42937932-56E99A83-4E85-4FA8-ACF4-28D9294996AC

P2860

Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.

http://www.wikidata.org/entity/Q34150018

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Class I histone deacetylase in ...... al and prostate cancer models.

@ast

Class I histone deacetylase in ...... al and prostate cancer models.

@en

Class I histone deacetylase in ...... al and prostate cancer models.

@nl

type

label

Class I histone deacetylase in ...... al and prostate cancer models.

@ast

Class I histone deacetylase in ...... al and prostate cancer models.

@en

Class I histone deacetylase in ...... al and prostate cancer models.

@nl

prefLabel

Class I histone deacetylase in ...... al and prostate cancer models.

@ast

Class I histone deacetylase in ...... al and prostate cancer models.

@en

Class I histone deacetylase in ...... al and prostate cancer models.

@nl

P1433

Q34150018-4EDB8212-F045-48BD-A2BA-72F3BCCBA6FC

P1476

Q34150018-7E02F0A2-CA03-4DE5-9207-B6C79B1A2499

P2093

Q34150018-069ABB44-32C7-4E4D-B115-B1944FD578F9

Q34150018-08DA3F34-B710-421F-851B-1E69289F04B3

Q34150018-261B2A83-54F3-44C1-B5AC-323967B3D7B5

Q34150018-28FA28A9-6F38-4A1C-95DC-CF27D04368AD

Q34150018-60E2F285-75BC-4422-97F9-2F7AB767E25C

Q34150018-873E285C-34EC-4C2B-8B6A-8C6D076261CB

Q34150018-F197887B-E19D-4A9E-9F86-BA0AC40CD237

Q34150018-F459D048-0F85-4C62-B8B7-B11F8FCACE59

Q34150018-FD6766E0-8408-4FE6-9361-655BA0475CA3

P2860

Q34150018-044C9892-025A-41AB-9E89-FA03BD33BD86

Q34150018-05AB174D-C828-4020-8588-E6F0778AB7F7

Q34150018-08A3B91F-A34D-42FD-AE15-B14C0D443822

Q34150018-0D3F7C43-A341-4023-8F08-D774A67AEFEA

Q34150018-0FCB03EA-4F70-4B0D-9E23-EA13A0370E96

Q34150018-1755F38B-FAF3-41B2-B7B8-D1DBB594721F

Q34150018-18152DA6-B09F-41C1-BDF5-F045E9BC8CB7

Q34150018-1B19D242-00E8-46BC-BC0B-AEDFDA190E9C

Q34150018-290EA5CE-9E7F-4B50-8D6A-5103937B7263

Q34150018-294D695A-278A-493B-8668-FD165AE34AA2

P304

Q34150018-BC17FC05-B513-4878-8912-58E75E15CCB2

P31

Q34150018-B64EE787-B5CE-4732-B9DE-5A3A203D1CCB

P356

Q34150018-E11C46BD-4F63-4C2A-BCED-633C77DFFC2E

P407

Q34150018-AE6D1ED1-3049-4579-BD5A-3F52AFDB5954

P433

Q34150018-2C8A34A2-F94E-4F3E-8513-D097C25C8ECC

P478

Q34150018-73D7A02C-DD6A-4B03-9C5C-DEC6CF3A7B96

P577

Q34150018-87D3899F-61B2-4F49-B85F-A0271A8CF5A1

P5875

Q34150018-C62FADA0-C5DC-425D-BC11-06BDA4E34937

P698

Q34150018-85CE222B-1982-4DB8-9F8C-EDD12439189C

P921

Q34150018-9D6FEEEE-CF68-48C9-8CF9-E0EB9BC30AB9

P932

Q34150018-C31E84C2-35ED-40CF-BA68-29CF35B5E7BE

P356

JOURNAL.PONE.0030815

P1433

P1476

Class I histone deacetylase in ...... al and prostate cancer models.

@en

P2093

Kiersten M Miles

http://www.w3.org/2001/XMLSchema#string

Leigh Ellis

http://www.w3.org/2001/XMLSchema#string

Li Shen

http://www.w3.org/2001/XMLSchema#string

Michael Ciesielski

http://www.w3.org/2001/XMLSchema#string

Paula Sotomayor

http://www.w3.org/2001/XMLSchema#string

Protul Shrikant

http://www.w3.org/2001/XMLSchema#string

Robert Fenstermaker

http://www.w3.org/2001/XMLSchema#string

Roberto Pili

http://www.w3.org/2001/XMLSchema#string

Swathi Ramakrishnan

http://www.w3.org/2001/XMLSchema#string

P2860

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

Foxp3 programs the development and function of CD4+CD25+ regulatory T cells

Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation

Acetylation and deacetylation of non-histone proteins

Specific activity of class II histone deacetylases in human breast cancer cells

The IL-6R alpha chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo.

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

Stat3 dimerization regulated by reversible acetylation of a single lysine residue.

CD4(+) regulatory T cells.

Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.

P304

e30815

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0030815

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-01-27T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221804138

http://www.w3.org/2001/XMLSchema#string

P698

22303460

http://www.w3.org/2001/XMLSchema#string

P921

P932

3267747

http://www.w3.org/2001/XMLSchema#string